Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Everolimus Post-Bland Hepatic Artery Embolization in Patients With Neuroendocrine Tumors (NETs) With Liver Metastasis

12 novembre 2026 mis à jour par: Lowell Anthony, MD

Phase 2 Dose Optimization Trial of Everolimus Post-Bland Hepatic Artery Embolization (Evero-Embo) in Patients With Neuroendocrine Tumors (NETs) With Liver Metastasis

This study is being done to learn whether people with neuroendocrine tumors (NETs) that have spread to the liver can safely tolerate a lower dose of everolimus after bland hepatic artery embolization (HAE).

Aperçu de l'étude

Type d'étude

Interventionnel

Inscription (Estimé)

12

Phase

  • Phase 2

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

  • Nom: Lowell B Anthony, MD
  • Numéro de téléphone: 859-257-4488
  • E-mail: lan225@uky.edu

Lieux d'étude

    • Kentucky
      • Lexington, Kentucky, États-Unis, 40536
        • University of Kentucky
        • Contact:
          • Lowell B Anthony, MD
          • Numéro de téléphone: 859-257-4488
          • E-mail: lan225@uky.edu
        • Chercheur principal:
          • Lowell B Anthony, MD

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Patients must have histologically or cytologically confirmed Grade 1 or 2 NET with measurable liver metastasis (≥1.0 cm).
  • Morphologically progressive disease by RECIST 1.1 and/or ≥25% but ≤75% tumor burden in the liver.
  • Prior tolerance of at least 5 mg daily everolimus for ≥5 days pre-HAE. NOTE: There is no maximum amount of time a patient may be taking Everolimus before HAE as the study focuses on after the pre-HAE dose is established.
  • Prior therapy: Patients are eligible regardless of the number or type of prior therapies and without a requirement to have received a specific therapy prior to enrollment. Patients will take everolimus leading up to the embolization once enrolled in the study. They will only be enrolled in the study for their first hepatic artery embolization. They must be 30 days out since their last cancer treatment of any kind, not including somatostatin analogs.
  • Age ≥18 years.
  • ECOG performance status ≤2 (see Appendix A).
  • Patients must have adequate organ and marrow function as defined below:
  • absolute neutrophil count ≥1,000/mcL
  • platelets ≥100,000/mcL
  • total bilirubin ≤ institutional upper limit of normal (ULN)
  • Child-Turcotte-Pugh class A; B dose reduction is recommended at 5mg QD or less; C recommend non-usage of everolimus
  • Creatinine (or GFR) ≤ institutional ULN (Appendix B)
  • GFR, glomerular filtration rate (or creatinine) There are no dose reductions required for patients in any stage of renal failure for everolimus
  • Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.
  • For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.
  • Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.
  • Patients with a prior malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
  • Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better.
  • Ability to understand and the willingness to sign a written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants.

Exclusion Criteria:

  • Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > Grade 1) with the exception of alopecia.
  • Prior transhepatic artery embolization.
  • Contraindication to arteriography or embolization.
  • Prior chemotherapy or peptide receptor radionuclide therapy within 1 month.
  • Biliary stent or choledocho-enteric anastomosis.
  • Patients who are receiving any other investigational agents for the treatment of this cancer.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to everolimus
  • Concomitant medications: Patients should only be excluded from trial participation when clinically relevant known or predicted drug-drug interactions or potential overlapping toxicities will impact safety or efficacy. Drug-drug interactions of risk level X will be excluded from the trial unless an alternative medication can be substituted. Drug-drug interactions are classified into classes A, B, C, D and X. A Class X drug interaction represents a high-risk, contraindicated combination where the risks of taking the medications together clearly outweigh any potential benefits. These medications include Antihepaciviral Combination Products, BCG Products, Brivudine, Chikungunya Vaccine (Live), Chloramphenicol (Systemic), Cladribine, Dengue Tetravalent Vaccine (Live), Etrasimod, Fexinidazole, Grapefruit Juice, Inhibitors of CYP3A4 (Strong) and P-glycoprotein, Mumps- Rubella- or Varicella-Containing Live Vaccines, Nadofaragene Firadenovec, Natalizumab, Pimecrolimus, Pimozide, Poliovirus Vaccines (Live/Oral), Tacrolimus (Topical), Talimogene Laherparepvec, Tertomotide, Thiamphenicol, Typhoid Vaccine, Vaccines (Live), Yellow Fever Vaccine, Zoster Vaccine (Live/Attenuated). Additionally, patients should avoid taking everolimus while on strong CYP3A4 inhibitors. They should have everolimus dose reduction to 2.5 mg PO while on moderate CYP34A inhibitors and/or PgP inhibitors. An increase in everolimus dose is recommended when co-administered with a strong CYP3A4 inducer (see package insert, Appendix C).
  • Patients with uncontrolled intercurrent illness.
  • Pregnant women are excluded from this study because everolimus is an mTOR inhibitor agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with everolimus, breastfeeding should be discontinued if the mother is treated with everolimus. NOTE: Patients treated with everolimus should use highly effective birth control during treatment and for 8 weeks after their last everolimus dosing. Male patients with female partners of reproductive potential should be advised to use effective contraception during treatment with everolimus and for 4 weeks after the last dose

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: N / A
  • Modèle interventionnel: Affectation à un seul groupe
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Everolimus following Bland Hepatic Artery Embolization

Everolimus 5mg will be provided orally for 7 days pre embolization then every other day beginning day 2 through day 30, post embolization. Bland Hepatic Artery procedure will occur on Day 0.

Everolimus 5mg will be provided orally for 7 days pre embolization then every other day beginning day 2 through day 30, post embolization

Bland Hepatic Artery Embolization (HAE) will occur on Day 0.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Percentage of patients who can tolerate everolimus pre and post HAE
Délai: Pre-study to Day 30

To assess the percentage of patients who can tolerate ½ pre-embolization everolimus dose administered every other day post-bland hepatic artery embolization of liver metastasis in neuroendocrine tumor (NET) patients (dose optimization trial).

Pre-study to Day 30

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Objective Response Rate
Délai: Pre-study to Day 30

To determine the objective response rate (ORR) and hepatic progression-free survival (hPFS).

Pre-study to Day 30
Progression Free Survival
Délai: Pre-study to Day 30

To determine the objective response rate (ORR) and hepatic progression-free survival

Pre-study to Day 30
Biochemical Response
Délai: Pre-study to Day 30

To evaluate biochemical response using Chromogranin A (CGA), serotonin, and 5-HIAA levels, defined as a 50% reduction from baseline if elevated.

Pre-study to Day 30

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Les enquêteurs

  • Chercheur principal: Lowell B Anthony, MD, University of Kentucky

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

16 décembre 2026

Achèvement primaire (Estimé)

31 décembre 2028

Achèvement de l'étude (Estimé)

1 juillet 2029

Dates d'inscription aux études

Première soumission

12 novembre 2026

Première soumission répondant aux critères de contrôle qualité

12 novembre 2026

Première publication (Réel)

18 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

18 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

12 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner